Catalyst Biosciences, Inc. (NASDAQ:CBIO) Sees Large Increase in Short Interest

Catalyst Biosciences, Inc. (NASDAQ:CBIO – Get Rating) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 1,470,000 shares, an increase of 34.9% from the June 30th total of 1,090,000 shares. Currently, 6.3% of the company’s stock are short sold. Based on an average trading volume of 6,320,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Investors Weigh In On Catalyst Biosciences

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its holdings in Catalyst Biosciences by 187.9% during the first quarter. Bank of New York Mellon Corp now owns 216,807 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 141,498 shares in the last quarter. Acadian Asset Management LLC bought a new position in Catalyst Biosciences in the 4th quarter valued at $211,000. Finally, Assenagon Asset Management S.A. bought a new position in Catalyst Biosciences in the 4th quarter valued at $469,000. Institutional investors own 62.37% of the company’s stock.

Catalyst Biosciences Trading Down 1.1 %

Shares of Catalyst Biosciences stock opened at $1.75 on Monday. The stock has a fifty day simple moving average of $1.54 and a 200 day simple moving average of $0.92. Catalyst Biosciences has a 12-month low of $0.35 and a 12-month high of $5.20. The company has a market capitalization of $55.08 million, a P/E ratio of -0.69 and a beta of 1.51.

Catalyst Biosciences (NASDAQ:CBIO – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.10. Catalyst Biosciences had a negative return on equity of 149.54% and a negative net margin of 1,200.77%. The business had revenue of $0.79 million during the quarter. On average, analysts predict that Catalyst Biosciences will post -1.24 EPS for the current year.

Catalyst Biosciences Company Profile

(Get Rating)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system.